Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

Inclusion Criteria: * Receiving HD or PD for native kidney end-stage renal disease (ESRD) for 2 weeks to 4 months, prior to randomization * Mean of the 2 most recent Hb values during the screening period, obtained at least 7 days apart, must be \<10.0 grams (g)/deciliter (dL), with a difference of ≤1.0 g/dL between the 2 values * Body weight 40 to 140 kilograms (kg) Exclusion Criteria: * Previously received erythropoiesis-stimulating agents * Received IV iron within 4 weeks of randomization * Received red blood cell transfusion within 8 weeks prior to randomization or anticipated need for transfusion during the treatment period * Positive for any of the following: human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus antibody (anti-HCV Ab) * History of chronic liver disease * Clinically significant infection * New York Heart Association Class III or IV congestive heart failure * History of malignancy, except the following: cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell skin cancers, cervical cancer in situ, or resected colonic polyps * Chronic inflammatory disease that could impact erythropoiesis (for example, systemic lupus erythematosis, rheumatoid arthritis, celiac disease) even if it is currently in remission * History of other blood disorders * Active hemolysis or diagnosis of hemolytic syndrome * Known bone marrow fibrosis * Uncontrolled or symptomatic secondary…